ADHD Symptoms and Subtypes: Relationship Between Childhood and Adolescent Symptoms - 12/08/11
, JAMES J. McGOUGH, M.D., SANDRA K. LOO, Ph.D., MARJO-RIITTA JÄRVELIN, MD., Ph.D., IRMA K. MOILANEN, M.D., Ph.D.ABSTRACT |
Objective |
To study attention-deficit/hyperactivity disorder (ADHD) symptoms and DSM-IV subtypes in childhood and adolescence.
Method |
A total of 457 adolescents ages 16 to 18 years from the Northern Finland Birth Cohort 1986 participated in an epidemiological survey for ADHD. After assessment with a diagnostic interview those with current or childhood ADHD were classified using DSM-IV criteria. Childhood diagnosis of ADHD was set according to retrospective recall. The characteristics and relationships in ADHD symptomatology in childhood and adolescence were studied in relation to behavioral problems and parental history of attentional problems.
Results |
ADHD was reported more commonly in childhood than in adolescence and variations in subtype classification occurred. Those with childhood and adolescent diagnosis had endorsed specific inattentive symptoms more commonly, had greater comorbid major depression and/or oppositional defiant disorder, and had fathers with more reported attentional problems than those with only childhood diagnosis. In childhood, ADHD subtypes differed along symptom severity, but by adolescence these differences were no longer significant.
Conclusions |
The persistence of ADHD from childhood to adolescence may be common. Specific inattentive symptoms, certain psychiatric comorbidity, and family history of attention problems (fathers specifically) contribute to the risk of persistent ADHD. ADHD subtype differences reflect symptom severity differences in childhood that are negligible by adolescence.
Le texte complet de cet article est disponible en PDF.Key Words : attention-deficit/hyperactivity disorder, subtypes, change, childhood, adolescence
Plan
| The Graduate School of Circumpolar Wellbeing, Health, and Adaptation is acknowledged for its support. This research was supported byNational Institute of Mental HealthgrantsMH063706(Smalley, Järvelin) andMH01966(McGough), the Academy of Finland (Järvelin), The Juselius Foundation (Moilanen), The Thule Institute, University of Oulu (Moilanen), The Child Psychiatric Research Foundation (Hurtig), the YrjöJahnsson Foundation (Hurtig), and the Alma and KA Snellman Foundation (Hurtig). Disclosure: Dr. McGough receives grant research support from Eli Lilly, McNeil, New River Pharmaceuticals, Novartis, Shire, and Pfizer, is a consultant to Eli Lilly, Novartis, and Shire, and a speakers’ bureau member for Eli Lilly, McNeil, Novartis, and Shire. Dr. Moilanen is a member of the Lilly Strattera advisory board, Finland. The other authors have no financial relationships to disclose. |
Vol 46 - N° 12
P. 1605-1613 - décembre 2007 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
